Skip to content
BOLUS

Signal from the log

NeuShen Therapeutics

plus de 80 M$ · Series B · Chine, Etats-Unis · Biotech

NeuShen Therapeutics développe des molécules pour la psychiatrie et les maladies neurodégénératives, depuis Shanghai et Boston. Son composé le plus avancé, le laviclidine, est un modulateur allostérique positif du récepteur muscarinique M4, testé contre la schizophrénie et l'agitation liée à la maladie d'Alzheimer, et deux autres candidats sont en essai clinique. Le tour de table est mené par un industriel que la société ne nomme pas.

Verified

Announced on , logged by the watch of 4 September 2026.

Operation
Funding round
Announced amount
plus de 80 M$
Stage
Series B
Country
Chine, Etats-Unis
Sector
Biotech

What the log says

Editorial note, in French

Communiqué ouvert, montant relu et fonds nommés.

The investors

Led by Investisseur industriel non divulgue , with B Capital , Junlian Capital , Morningside Venture Capital , Realink Investment , Shanghai State-owned Investment Pioneer Fund

Provenance
Source endpoints
Logged on 4 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).